Aimed at helping the pharmaceutical industry avoid drug shortages and maintain a robust and reliable supply of medications to patients world-wide
ISPE, the International Society for Pharmaceutical Engineering, has released a preview of its Drug Shortages Prevention Plan aimed at helping the pharmaceutical industry avoid drug shortages and maintain a robust and reliable supply of medications to patients worldwide.
The Plan was developed by ISPE and its expert pharmaceutical and biopharmaceutical industry members and describes how industry can best prevent drug shortages from occurring by discovering root causes and through creating and sustaining organisational cultures supported by leadership, business processes and quality systems.
ISPE's Drug Shortages Prevention Plan was reviewed by regulators from the European Medicines Agency (EMA) and the Medicines and Healthcare Products Regulatory Agency (MHRA), with further regulatory review expected.
'Our goal is that the pharmaceutical industry will use the Plan not only to help them look holistically across the supply chain, but also as a roadmap to use in challenging their current processes, systems and practices and to identify potential gaps and risks,' said ISPE CEO and President Nancy Berg. 'Having the input of regulatory authorities has been invaluable to the effort because it helps to clarify what expectations regulators have regarding necessary steps toward drug shortage prevention and mitigation.'
The Plan was developed by the ISPE Drug Shortages Task Team that built upon the results of ISPE's landmark 2013 study on drug shortages and organised their effort around a 'six dimension' framework comprised of:
In each chapter, the Plan provides answers to questions posed within each of the six dimensions, and also offers 'real world' case studies that illustrate how best practices can be established.
To ensure a comprehensive approach, the Task Team engaged with leaders from more than 30 major pharmaceutical companies and for more than a year, gathered stakeholder input from hundreds of industry professionals at ISPE's conferences and workshops. Industry senior management, with considerable influence on organisational culture and alignment, were engaged in the process.
'One thing the Task Team learned from their interviews with members of industry was that quality systems can only be effective where there is a strong emphasis on a “corporate quality culture” throughout the organisation,' said Francois Sallans, Vice President and Chief Quality Officer, Johnson & Johnson, and chair of the ISPE Drug Shortages Task Team.
'This became clear when data from the 2013 Survey was analysed, but it became even more apparent when the Team linked a quality culture to the other elements, such as metrics and capacity building. We hope companies can use the Plan as a “toolbox” from which they can select the drug shortage prevention tools most appropriate for them.'
According to Berg, ISPE’s 2013 study on drug shortages provided clear evidence that mitigating shortages requires a holistic approach that includes careful alignment of organizational aspects—people—as well as the technical aspects of process and production in understanding risks and signals indicating a drug shortage may be possible. The Plan builds on this data and incorporates significant follow-up input from stakeholders on how drug shortages can be prevented.
ISPE will release the complete Drug Shortages Prevention Plan during the 2014 ISPE Annual Meeting that will be held 12 - 15 October in Las Vegas, Nevada, US. Download the ISPE Drug Shortages Prevention Plan Introductory Summary.